Clinical Investigation of Corneal Incision Size After Intraocular Lens (IOL) Implantation
Clinical Investigation of Corneal Incision Size After IOL Implantation With Preloaded Delivery Devices and a Manual Delivery Device
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to comprehend and sign a statement of informed consent;
- Willing and able to complete all required postoperative visits;
- Cataract;
- Planned cataract removal by phacoemulsification;
- Calculated lens power from 18.0 through 27.0 D inclusive;
- Preoperative astigmatism <1.0D;
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- Systemic disease that affects the cornea;
- Any inflammation or edema of the cornea;
- Previous or planned refractive or corneal surgery during the subject's participation in the study;
- Previous corneal transplant;
- Previous retinal detachment;
- Pregnancy or lactation, current or planned, during the course of the study;
- Current participation in another investigational drug or device study that may confound the results of this investigation;
- Any condition observed before or during surgery that in the surgeon's medical opinion may affect the success of the cataract surgery;
- Other protocol-specified exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: UltraSert Preloaded Delivery System
Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
|
Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
|
|
Active Comparator: iTec Preloaded Delivery System
Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
|
Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
|
|
Active Comparator: iSert Preloaded Delivery System
Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
|
Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
|
|
Active Comparator: Monarch III D Manual IOL Delivery System
Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery
|
Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Corneal Incision Size After IOL Implantation (UltraSert, iTec, and iSert)
Time Frame: Day 0, operative day
|
Post-IOL implantation corneal incision size was measured directly after IOL implantation and reported in millimeters (mm).
Minimizing enlargement of incision size during cataract surgery results in less postoperative inflammation, less surgically-induced astigmatism, and more rapid visual and wound rehabilitation.
This endpoint was prespecified for the UltraSert, iTec, and iSert preloaded delivery systems.
Only one eye (study eye) contributed to the analysis.
|
Day 0, operative day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Corneal Incision Size After IOL Implantation (UltraSert and Monarch III D)
Time Frame: Day 0, operative day
|
Post-IOL implantation corneal incision size was measured directly after IOL implantation and reported in millimeters (mm).
Minimizing enlargement of incision size during cataract surgery results in less postoperative inflammation, less surgically-induced astigmatism, and more rapid visual and wound rehabilitation.
This endpoint was prespecified for the UltraSert preloaded delivery system and the Monarch III D delivery system.
Only one eye (study eye) contributed to the analysis.
|
Day 0, operative day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Sr. Clinical Manager, GCRA, Alcon Research
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ILN296-P001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataracts
-
NCT05575063Completed
-
NCT02492659Completed
-
NCT01936714Completed
-
NCT00827073Completed
-
NCT00999492Completed
-
NCT01936727Completed
Clinical Trials on UltraSert Preloaded Delivery System
-
NCT03824028Completed
-
NCT07288086Active, not recruitingIntraocular Lens | Cataract Surgery
-
NCT05689125CompletedEndotracheal Intubation | Simulation | Cardiopulmonary Resuscitation
-
NCT02724384Unknown
-
NCT01419015Completed
-
NCT00116571TerminatedProstatic Hyperplasia